Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anadys reports encouraging results from Phase I hepatitis study
In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400mg, 800mg, 1400mg, 2000mg and 3000mg. In addition, a separate
In the Phase I study in healthy volunteers, ANA598 was administered as capsules at single oral doses of 400mg, 800mg, 1400mg, 2000mg and 3000mg. In addition, a separate
The Phase I studies are open-label, dose-escalating clinical trials in patients with incurable breast, bladder, pancreatic, or colorectal cancer, all tumors that can express hCG Beta. The studies
The TalentManager platform provides configurable pay-for-performance capabilities that can be mapped to a customer’s business requirements and internal processes. A flexible set of in-depth compensation and performance management
The agreement also includes the transfer of marketing-authorization for Concor, an anti-hypertensive medication, and Glucophage, a diabetes agent. It is the second agreement that Daiichi Sankyo and Merck
Mr Kohlbecher, who will be based in Germany, fills this newly created position to oversee all of Alphatec Spine’s European operations. Mr Kohlbecher will be responsible for directing
Mobile Diagnostic Centers, a mobile imaging services provider, hired Dr McNamara as director of marketing and operations in June 2008 with the original intention of having him replace
The grants are part of Delivering Hope, an umbrella program for Bristol-Myers Squibb’s efforts in the areas of hepatitis awareness, prevention and care. A total of five grants
Prior to joining Vnus, Dr Smeets served as the head of clinical affairs for Pelikan Technologies, a privately held diagnostic testing platform company. Dr Smeets holds a doctor
In this position, Dr Kelly will develop strategies to improve the health and wellness of the users of Lifeclinic’s blood pressure monitors, health stations, and health management systems.
Savient’s filing includes data from both the six-month placebo controlled Phase III pivotal trials, as well as data from the open label extension study. The data set includes